These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21031169)

  • 1. Chemical & biological therapeutic approaches to neurological disorders.
    François I
    Drug News Perspect; 2010 Oct; 23(8):524-31. PubMed ID: 21031169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finding new cures for neurological disorders: a possible fringe benefit of biodefense research?
    Jett DA
    Sci Transl Med; 2010 Mar; 2(23):23ps12. PubMed ID: 20375001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug targeting strategies into the brain for treating neurological diseases.
    Barnabas W
    J Neurosci Methods; 2019 Jan; 311():133-146. PubMed ID: 30336221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages of Structure-Based Drug Design Approaches in Neurological Disorders.
    Aarthy M; Panwar U; Selvaraj C; Singh SK
    Curr Neuropharmacol; 2017 Nov; 15(8):1136-1155. PubMed ID: 28042767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysthymia in neurological disorders.
    Akiskal HS; Bolis CL; Cazzullo C; Costa e Silva JA; Gentil V; Lecrubier Y; Licinio J; Linden M; Lopez-Ibor JJ; Ndiaye IP; Pani L; Prilipko L; Robertson MM; Robinson RG; Starkstein SE; Thomas P; Wang Y; Wong ML
    Mol Psychiatry; 1996 Dec; 1(6):478-91. PubMed ID: 9154250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Chemical Society-239th national meeting--Investigating new therapeutic candidates: part 1. 21-25 March 2010, San Francisco, CA, USA.
    Macauley D
    IDrugs; 2010 May; 13(5):289-91. PubMed ID: 20432180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal treatment options for neurological disorders: impact on the elderly.
    Priano L; Gasco MR; Mauro A
    Drugs Aging; 2006; 23(5):357-75. PubMed ID: 16823990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for detection, prognosis and therapeutic assessment of neurological disorders.
    Singh S; Gupta SK; Seth PK
    Rev Neurosci; 2018 Sep; 29(7):771-789. PubMed ID: 29466244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of biological therapies for neurological diseases: moving on from previous failures.
    Qosa H; Volpe DA
    Expert Opin Drug Discov; 2018 Apr; 13(4):283-293. PubMed ID: 29394876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from black pepper: piperine and derivatives thereof.
    Chavarria D; Silva T; Magalhães e Silva D; Remião F; Borges F
    Expert Opin Ther Pat; 2016; 26(2):245-64. PubMed ID: 26560940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purinergic Signalling and Neurological Diseases: An Update.
    Burnstock G
    CNS Neurol Disord Drug Targets; 2017; 16(3):257-265. PubMed ID: 27658510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin: A review of its potential functions and effects on neurological diseases.
    Gunata M; Parlakpinar H; Acet HA
    Rev Neurol (Paris); 2020 Mar; 176(3):148-165. PubMed ID: 31718830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in metabolomics in neurological disease, and future perspectives.
    Zhang AH; Sun H; Wang XJ
    Anal Bioanal Chem; 2013 Oct; 405(25):8143-50. PubMed ID: 23715678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galanin receptors as a potential target for neurological disease.
    Freimann K; Kurrikoff K; Langel Ü
    Expert Opin Ther Targets; 2015; 19(12):1665-76. PubMed ID: 26220265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid system functional regulation in neurological disease management.
    Nandhu MS; Naijil G; Smijin S; Jayanarayanan S; Paulose CS
    J Neurosci Res; 2010 Nov; 88(15):3215-21. PubMed ID: 20734417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders.
    Sanchez-Barcelo EJ; Rueda N; Mediavilla MD; Martinez-Cue C; Reiter RJ
    Curr Med Chem; 2017 Nov; 24(35):3851-3878. PubMed ID: 28721826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders.
    Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G
    Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of WO2011045166A1, Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction.
    Zheng F; Zhang B; Sun Y; Qiu M; Su J
    Expert Opin Ther Pat; 2015 Jul; 25(7):831-5. PubMed ID: 25945965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurology: the near future].
    Inzitari D; Poggesi A
    Recenti Prog Med; 2006 Dec; 97(12):670-8. PubMed ID: 17252725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A report from the American Academy of Neurology 2014 Annual Meeting (April 26-May 3 - Philadelphia, Pennsylvania, USA).
    Rabasseda X
    Drugs Today (Barc); 2014 Jun; 50(6):445-60. PubMed ID: 24983592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.